Buparlisib (BKM120, NVP-BKM120)

目录号：S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献38篇：

客户使用该产品的6个实验数据：

  • NLGN3 mRNA expression in SU-pcGBM2 cells after 12 hr exposure to vehicle, 50 nM NLGN3, 100 nM BKM120, or 50 nM NLGN3 + 100 nM BKM120.

    Cell, 2017, 161(4):803-16. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Western blot analysis of cleaved caspase 3 in T cell-enriched PBMCs.

    J Hematol Oncol, 2016, 9(1):113. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • AN3CA (A) and JHUEM2 (B) cells were treated for the indicated times with DMSO, 0.3 μM BGJ398 (BGJ), 0.3 μM GDC-0941 (GDC), 0.6 μM BYL719 (BYL) and 0.6 μM BKM120 (BKM) alone or in combination. Cell lysates were immunoblotted with antibodies for phospho-AKT (Ser473), total AKT, phospho-ERK (Thr202/Tyr204), ERK2, phospho-S6 (Ser240/244), total S6, phospho-4EBP1 (Thr37/46), total 4EBP1, total PARP and cleaved PARP. Tubulin was detected as the loading control. Western blot analysis of AN3CA and JHUEM2.

    Mol Cancer Ther, 2017, 16(4):637-648. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of BKM120 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

  • One customer. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

    Dr. Pilar Eroles of INCLIVA Biomedical Research Institute.. Buparlisib (BKM120, NVP-BKM120) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 p110β [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NIjEUWJEgXSxdH;4bYMhSXO|YYm= M2L5SFczKGh? Mo\USG1UVw>? Mn:4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= NU\iVHlzOjR7MECyOlY>
DU145 M2jOVGN6fG:2b4jpZ{BCe3OjeR?= M{\ZU|czKGh? M3nERWROW09? MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? NX;jT|NxOjR7MECyOlY>
A2780 MW\DfZRwfG:6aXOgRZN{[Xl? MnXaO|IhcA>? MlX0SG1UVw>? MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBRXEWQLXTl[olkcWWwdDDoeY1idiCDMke4NEBk\WyuczD3bZRpKEeLNUCgc4YhOC5yMEC2N|Uh|ryP NFnm[mkzPDlyMEK2Oi=>
U87MG MY\DfZRwfG:6aXOgRZN{[Xl? MmThO|IhcA>? NF\KW21FVVOR M2G5[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= MlHvNlQ6ODB{Nk[=
A2780 NFrCbnFHfW6ldHnvckBCe3OjeR?= NUfxfnpoOSCq MVLEUXNQ NXPvelRFUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKHerdHigSWM2OCCxZjCwMlA2PSEQvF2= NVPRNppUOjR7MECyOlY>
DU145 Mn3kSpVv[3Srb36gRZN{[Xl? Mly3NUBp MkTVSG1UVw>? NHzjOHdKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hTFVzNEWgZ4VtdHNiaHHyZo9zcW6pIFzLRlEhdXW2YYTpc44hf2m2aDDFR|UxKG:oIECuNFc{KM7:TR?= NFTDXJAzPDlyMEK2Oi=>
A2780 NFPpZYVHfW6ldHnvckBCe3OjeR?= M3PL[FEhcA>? MVzEUXNQ MkntTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiRVO1NEBw\iByLkC3OEDPxE1? MoTtNlQ6ODB{Nk[=
MCF7 MlfoSpVv[3Srb36gRZN{[Xl? MVyxJIg> NEHvXnpFVVOR MXXJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> MomyNlQ6ODB{Nk[=
U87MG M2LDW2Z2dmO2aX;uJGF{e2G7 MX:xJIg> M4rFV2ROW09? Mnz6TY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiRVO1NEBw\iByLkGzJO69VQ>? MVGyOFkxODJ4Nh?=
A2780 M3j1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm3NkBp MoTsSG1UVw>? MUPFR|UxRTBwNUKg{txO NW\TV|FKOjR7MECyOlY>
SKMES-1 NX2zSXhNS3m2b4TvfIlkKEG|c3H5 NGLwPJQyKM7:TR?= NX60XII5PzJiaB?= NIDhd45KdmS3Y3XzJINmdGxiZHXheIg> M1PVb|I3ODF|M{G4
H596 NVLEUnc5TnWwY4Tpc44hSXO|YYm= NX;zS4hYOSEQvF2= MV\JcZBicXK|IHPlcIwhdWmpcnH0bY9v NVe5S|Z2OjZyMUOzNVg>
HCC2450 MUDGeY5kfGmxbjDBd5NigQ>? NXPuXYdCOSEQvF2= Mn3HTY1x[Wm{czDj[YxtKGmwdnHzbY9v NHzJbGszPjBzM{OxPC=>
A549 NHTPS5dHfW6ldHnvckBCe3OjeR?= M{na[FUxOCCwTR?= NYXsUnJ{PDhiaB?= MX;EUXNQ M4DyVmlvcGmkaYTzJGFsfCCjY4TpeoF1cW:w NVzD[25[OjV7M{eyPVk>
A549 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3rNUDPxE1? NUDi[FFLPzJiaB?= NHr1RoxFVVOR MmmxTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVPtfIZ4OjV7M{eyPVk>
H522 NU\MRW1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:wcJkyKM7:TR?= NW\Je4xZPzJiaB?= NYK3NVJJTE2VTx?= NF7CV2xKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NXr4WZBqOjV7M{eyPVk>
LNCaP MmrtSpVv[3Srb36gRZN{[Xl? MVexJO69VQ>? M3GyPXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NFvTOVYzPTN4MEe5PS=>
LNCaP95 MVLGeY5kfGmxbjDBd5NigQ>? M2PPWFEh|ryP NEnHWYJUfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= MmHONlU{PjB5OUm=
HCT-15 MWLBdI91d3OrczDBd5NigQ>? MkTKNVAh|ryP M1XERVQ5KGh? NXnDXpZ7TE2VTx?= NHXRXYpKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MmHtNlUyPTJ{NEW=
HCT-116 NILhRWNCeG:2b4Ppd{BCe3OjeR?= MVixNEDPxE1? MmnqOFghcA>? NH\YdGNFVVOR NHmyRmhKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVE3KGOnbHzzJIhiemKxdYLpcochWEmNM1PBJIhwfHOyb4SgcZV1[XSrb36= MkjuNlUyPTJ{NEW=
NCI-H460 NXfJSoxlSXCxdH;zbZMhSXO|YYm= NI\j[4MyOCEQvF2= MoDqOFghcA>? M3zvfmROW09? NWnN[m96UW6mdXPld{BieG:ydH;zbZMhcW5iTlPJMWg1PjBiY3XscJMhcGG{Yn;1dolv\yCSSVuzR2EhcG:2c4DveEBufXSjdHnvci=> NYTIVm93OjVzNUKyOFU>
SKOV-3 MUnBdI91d3OrczDBd5NigQ>? NEHOS5IyOCEQvF2= M1jXU|Q5KGh? MX7EUXNQ M4G0Omlv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w MkLCNlUyPTJ{NEW=
BSY-1 NXnndXVbSXCxdH;zbZMhSXO|YYm= NFvNTmQyOCEQvF2= Ml20OFghcA>? NG[yWFBFVVOR NInlbJBKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCEU2mtNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M3fxT|I2OTV{MkS1
MKN-1 MWPBdI91d3OrczDBd5NigQ>? NHPJN4oyOCEQvF2= MVq0PEBp M4XWd2ROW09? NG\hV4JKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCPS16tNUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w NYHIPW5HOjVzNUKyOFU>
NCI-H522 Mn6yRZBwfG:|aYOgRZN{[Xl? NH3mO2oyOCEQvF2= MkfVOFghcA>? MlrWSG1UVw>? MkjyTY5lfWOnczDhdI9xfG:|aYO= MVyyOVE2OjJ2NR?=
OVCAR-3 NIfhWVJCeG:2b4Ppd{BCe3OjeR?= NX7Y[I1yOTBizszN MnLYOFghcA>? NIPDdFBFVVOR M1XFUGlv\HWlZYOgZZBweHSxc3nz NEDxRYczPTF3MkK0OS=>
HBC-5 M333UmFxd3Sxc3nzJGF{e2G7 Mnj3NVAh|ryP MWC0PEBp M1f0fWROW09? MkLiTY5lfWOnczDhdI9xfG:|aYO= M{DOeFI2OTV{MkS1
RXF-631L MlrwRZBwfG:|aYOgRZN{[Xl? NXnQXGdVOTBizszN NXXvXpJyPDhiaB?= M17NXWROW09? MYnJcoR2[2W|IHHwc5B1d3Orcx?= M{Dn[FI2OTV{MkS1
MKN-45 NXvEdJZQSXCxdH;zbZMhSXO|YYm= MoXmNVAh|ryP NVT2T3BsPDhiaB?= NXywbGJGTE2VTx?= Mk[3TY5lfWOnczDhdI9xfG:|aYO= Mo\nNlUyPTJ{NEW=
BON-1 NVzFfndpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIO2V3U2ODBibl2= NWj3TFY4OTBiZB?= M{PtZmROW09? NYK1blN3UW6qaXLpeJMh[2WubDDndo94fGh? MXiyOVAzPjJ7Mh?=
BON-1 NWH0N4pETnWwY4Tpc44hSXO|YYm= NV\SWohkPTByIH7N MYm0JIg> M1rLZWROW09? NFrBN4pKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez NIrrepAzPTB{NkK5Ni=>
QGP-1 M{D2V2Z2dmO2aX;uJGF{e2G7 MlPLOVAxKG6P MVW0JIg> M3j1dmROW09? M3vRXWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1RiYYSgWIhzOzB6IHHu[EBU\XJ2N{O= MkXmNlUxOjZ{OUK=
Huh7 NU\vWHFLTnWwY4Tpc44hSXO|YYm= NWTjR2dGOSEQvF2= M2nlflEhcA>? NUPUTlk3TE2VTx?= NWDlb|RvUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= MnvLNlUxODR2MEO=
BNL NUfMTpdoTnWwY4Tpc44hSXO|YYm= M3\xS|Eh|ryP MX6xJIg> MYjEUXNQ M3jHeGlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? M2fkOlI2ODB2NECz
MDA-MB-175 M33DUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LGVlEh|ryP NUHRfHIxPSCm NUPkPFZWTE2VTx?= M{jDTWlEPTB:MTFOwG0> NIjEWFEzPDh5OUe5Oi=>
MDA-MB-134 NEG2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorUNUDPxE1? NVnMXXNZPSCm M1;sXWROW09? M1vDUWlEPTB:MTFOwG0> NFvrT4EzPDh5OUe5Oi=>
HCC1500 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxJO69VQ>? NYS1fnQyPSCm NFn0VFBFVVOR NEfsT4lKSzVyPEGg{txO NXj0N45GOjR6N{m3PVY>
EFM-19 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnkPIIzOSEQvF2= NUHQSXhJPSCm M{KwT2ROW09? NIDnfmhKSzVyPEGg{txO MW[yOFg4QTd7Nh?=
ZR-75-30 NIOySllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWyTJFIOSEQvF2= Ml6xOUBl MXzEUXNQ NG\sXWlKSzVyPEGg{txO NFHGNGMzPDh5OUe5Oi=>
MDA-MB-361 NIP2cHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmxJO69VQ>? MojCOUBl MoXCSG1UVw>? NF3ZUpJKSzVyPEGg{txO NWi2c2VVOjR6N{m3PVY>
T-47D MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojrNUDPxE1? NF;Ue3Y2KGR? NH3lOJdFVVOR M3vsOmlEPTB:MTFOwG0> MYiyOFg4QTd7Nh?=
SK-BR-3 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKxJO69VQ>? Mn3wOUBl NFizfpBFVVOR NEnjcIdKSzVyPEGg{txO MlH2NlQ5Pzl5OU[=
UACC-732 NF;VeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wNUDPxE1? M{X6O|Uh\A>? NGnrW49FVVOR MoPpTWM2ODxzIN88US=> NH7NboEzPDh5OUe5Oi=>
BT-474 NVrBfIM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj0O3V6OSEQvF2= NEXPdGc2KGR? NVjnSGtvTE2VTx?= NVjCWHJUUUN3MEyxJO69VQ>? M3HlUVI1QDd7N{m2
HCC202 M4\hSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4roVVEh|ryP MlTIOUBl NH;PUXVFVVOR MYnJR|UxRDFizszN NXTRdGZXOjR6N{m3PVY>
MCF7 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG3XWdlOSEQvF2= Mn7TOUBl M1jCUWROW09? MWHJR|UxRDFizszN MXOyOFg4QTd7Nh?=
MDA-MB-415 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV35R4ZMOSEQvF2= MWe1JIQ> NHjO[I1FVVOR NYPUSpM3UUN3MEyxJO69VQ>? M{S4UVI1QDd7N{m2
MDA-MB-453 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzWT44yKM7:TR?= Mlv1OUBl M2rxWmROW09? M3;TPGlEPTB:MTFOwG0> M2DZSlI1QDd7N{m2
ZR-75-1 NFe3UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PyS|Eh|ryP M2T0SFUh\A>? M3H3WmROW09? MoDmTWM2ODxzIN88US=> MYCyOFg4QTd7Nh?=
HCC38 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j4TlEh|ryP M3zIXFUh\A>? MYXEUXNQ M2\sZWlEPTB:MTFOwG0> MmG1NlQ5Pzl5OU[=
HCC1419 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M135RlEh|ryP NVq4[oI1PSCm MYXEUXNQ NInyPXhKSzVyPEGg{txO MmjDNlQ5Pzl5OU[=
UACC-812 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CwV|Eh|ryP M1LrblUh\A>? M{O5OGROW09? MmftTWM2ODxzIN88US=> NYXj[417OjR6N{m3PVY>
HCC1187 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxJO69VQ>? MUi1JIQ> M1;FRWROW09? NXHhVGFMUUN3MEyxJO69VQ>? MoHINlQ5Pzl5OU[=
KPL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1XYFmOSEQvF2= MVW1JIQ> M13yOWROW09? NV;rbIluUUN3MEyxJO69VQ>? MVuyOFg4QTd7Nh?=
SUM-225 M1jKZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4SGttOSEQvF2= Mn;FOUBl NWrNZZFXTE2VTx?= MYrJR|UxRDFizszN M4TuR|I1QDd7N{m2
EFM-192A MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWruSmNPOSEQvF2= M{XQVlUh\A>? MlW2SG1UVw>? NGLOepRKSzVyPEGg{txO MY[yOFg4QTd7Nh?=
JIMT-1 M2S3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWxJO69VQ>? Mn[0OUBl MYPEUXNQ MkWyTWM2ODxzIN88US=> M1jvNFI1QDd7N{m2
HCC1143 NHOzO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jsWlEh|ryP NGPYXI02KGR? NW[5c5dRTE2VTx?= NX\GU4R3UUN3MEyxJO69VQ>? NFO3VFczPDh5OUe5Oi=>
HCC2218 NEHzdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWflU5hYOSEQvF2= Mn\iOUBl M3HXfGROW09? NX3LNpo6UUN3MEyxJO69VQ>? MYiyOFg4QTd7Nh?=
MDA-MB-468 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH4dWxiOSEQvF2= MmXoOUBl MmewSG1UVw>? MWPJR|UxRDFizszN M3fa[|I1QDd7N{m2
BT-20 NGL6WldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jub|Eh|ryP NILMSHM2KGR? MYfEUXNQ NFy0fFdKSzVyPEGg{txO MoewNlQ5Pzl5OU[=
MDA-MB-435 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELpbFUyKM7:TR?= MmXJOUBl Mnj5SG1UVw>? NXfVXldjUUN3MEyxJO69VQ>? NWX1O3dqOjR6N{m3PVY>
BT-549 NYDDTYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[yNoMyKM7:TR?= NWrjSmFxPSCm MXHEUXNQ Mn\vTWM2ODxzIN88US=> MlKyNlQ5Pzl5OU[=
HCC1806 NWP2TY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXOxJO69VQ>? M1zRZlUh\A>? Ml;NSG1UVw>? M1jaW2lEPTB:MTFOwG0> MnqwNlQ5Pzl5OU[=
HCC1937 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqxJO69VQ>? MVm1JIQ> M1nUPWROW09? NITq[2NKSzVyPEGg{txO NXjicZVUOjR6N{m3PVY>
Hs578T MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHNUDPxE1? NVXBNoFqPSCm M{m5ZmROW09? M4LR[WlEPTB:MTFOwG0> MX2yOFg4QTd7Nh?=
LN18 NHHBWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\z[4gzOjBizszN MnLaO|IhcA>? NFT5TVBFVVOR M{[yfGlEPTB:NTFOwG0> Mly5NlQ4PDFyN{S=
LN229 NEnocoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiyNEDPxE1? M13sVlczKGh? MVnEUXNQ NYLQOWFCUUN3MEy1JO69VQ>? MXeyOFc1OTB5NB?=
LNZ308 M3LrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT4NlAh|ryP M3HVeVczKGh? MlvKSG1UVw>? Ml\jTWM2ODx3IN88US=> Mkn3NlQ4PDFyN{S=
T98G NVnZSWlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGyNEDPxE1? Mn\wO|IhcA>? M{HGfWROW09? MUHJR|UxRDVizszN M3\odVI1PzRzMEe0
U87 M4jpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWyNEDPxE1? NXTrU2Z{PzJiaB?= MXjEUXNQ NIXTXopKSzVyPEWg{txO M3HtfVI1PzRzMEe0
LN18 Moj0SpVv[3Srb36gRZN{[Xl? NWfFUlQxPSEQvF2= M2L5SVI1KGh? MXzEUXNQ NXrPWVduUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MkLxNlQ4PDFyN{S=
LNZ308 M3r3U2Z2dmO2aX;uJGF{e2G7 M1Gwe|Uh|ryP M4[0N|I1KGh? MmHhSG1UVw>? MlrmTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>? M{XhcVI1PzRzMEe0
Saos-2 M1WxO2Z2dmO2aX;uJGF{e2G7 NWn5d5FFPTBizszN MkPSOFghcA>? MmPQTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? M{HBVFI1PzJ5Nk[w
MG-63 MnfCSpVv[3Srb36gRZN{[Xl? M4jYdFUxKM7:TR?= M37QXlQ5KGh? NXPBXIMxUW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MYCyOFczPzZ4MB?=
SJSA-1 Mnz0SpVv[3Srb36gRZN{[Xl? MYS1NEDPxE1? MY[0PEBp MWHJcohq[mm2czDj[YxtKGmwdnHzbY9v NVHkOYp2OjR5Mke2OlA>
Saos-2 MU\GeY5kfGmxbjDBd5NigQ>? MXK1NEDPxE1? NFLU[4Y1QCCq NHHyfYdKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v MV:yOFczPzZ4MB?=
MG-63 MV;GeY5kfGmxbjDBd5NigQ>? MoLVOVAh|ryP NF:yW2M1QCCq MlnZTY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW|c3nvci=> M3LBWVI1PzJ5Nk[w
SJSA-1 MWPGeY5kfGmxbjDBd5NigQ>? NXHCWVVnPTBizszN NYe0V4JQPDhiaB?= MXzJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u MnHzNlQ4Ojd4NkC=
Saos-2 NYDqfVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni5OVAh|ryP M3jZWVQ5KGh? MWnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M4\JfVI1PzJ5Nk[w
MG-63 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSyOVAh|ryP M3;IVVQ5KGh? M4\KSWlvcGmkaYTzJINmdGxidnnhZoltcXS7 MXSyOFczPzZ4MB?=
SJSA-1 NVzYd4o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzhOVAh|ryP M1nMdFQ5KGh? MYjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M4D2RVI1PzJ5Nk[w
FaDu NGHyTIVHfW6ldHnvckBCe3OjeR?= M2fReVUh|ryP MmLDNlQhcA>? NH\FS4pFVVOR NUfxPYtjWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> MVKyOFY{OTF2Nx?=
EMT6 NE\rSJRHfW6ldHnvckBCe3OjeR?= NYH4XZo{PSEQvF2= M{i2WVI1KGh? MmrXSG1UVw>? Ml7DVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MnHyNlQ3OzFzNEe=
HCT116 MV\GeY5kfGmxbjDBd5NigQ>? NGfJNI42KM7:TR?= NHnmdnEzPCCq NF7xT4RFVVOR M1XlOnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NEG3T2EzPDZ|MUG0Oy=>
U87 NHPkWFlHfW6ldHnvckBCe3OjeR?= NYizcpVXPSEQvF2= NH7HPGwzPCCq M{nOUWROW09? MX;S[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MkHENlQ3OzFzNEe=
GBM NIPqc2NCeG:ydH;zbZMhSXO|YYm= NVvYcolrOs7:TR?= MWi0PIg> MlfVSG1UVw>? MYTpcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 NVTIb|cxOjR3MEC0PVI>
BON Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320ZlEuPc7:TR?= MlTEO|Jp NXfDeYlv\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? M1exTVI1PDR|NUKz
BON NWDTZWVjSXCxcITvd4l{KEG|c3H5 NH7jUW0yNTYQvF2= MYeyOIg> M3PZPIlv[3KnYYPld{BieG:ydH;zbZM> MoixNlQ1PDN3MkO=
H1975 NW\6ZlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMlMuQS54zszN NF\BcI44Omh? NVXNTpZYTE2VTx?= MYPJR|UxRTFwM{i1{txO MorKNlQ{Ozd6NE[=
H1975 MmjKRZBweHSxc3nzJGF{e2G7 NWDZWnZXOs7:TR?= MUWyOIg> NXTMbGdxTE2VTx?= M4rrS4lv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 MU[yOFM{Pzh2Nh?=
T-ALL NVW5WGV4SXCxcITvd4l{KEG|c3H5 M{W2[IJmfHenZX6gNU41KGGwZDC1MlMhdU1iYYSgNlRpKGGwZDCwMlkh[W6mIEWuOUBuVSCjdDC0PIghcW5iZHnm[oVz\W62IHPlcIwhdGmwZR?= M3rYPVI1KG:{IES4bC=> NFnJTIRFVVOR MYXh[oZm[3S|IITo[UBRUTONIIDheIh4[XliaX6gWE1CVExiY3XscEBtcW6ncx?= M2HkRVI1OzFyN{O2
BCR-ABL NWP4RmFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm4dHYxNjJ3LUGw{txO NVrzSGx7PGR? NX3QNYd4e2mpbnnmbYNidnSueTDpcohq[mm2IHPlcIwheHKxbHnm[ZJifGmxbh?= MYiyOFI1PDZzMh?=
LC-1/SQSF M2jGTWZ2dmO2aX;uJGF{e2G7 NFLHd3E{|ryP NU\SeXJpOjSq NVzodYhwTE2VTx?= NELQbVFl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> MXSyN|k5ODB7Mx?=
Primary CLL cells NUHWSWMxSXCxcITvd4l{KEG|c3H5 M2[4N|EuOTEQvF2= NV;kepNbPDiq MWDpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz M3jEZ|I{QDVyOEC3
Primary CLL cells MlLIT4lv[XOnIFHzd4F6 MnW1Nu69VQ>? M{KwXVMxdWmw NXG3WVJz\GWlcnXhd4VlKFCLM1ugZYN1cX[rdIm= NWLod5JDOjN6NUC4NFc>
Primary CLL cells MmPXR5l1d3SxeHnjJGF{e2G7 MnHqNu69VQ>? MYCyOIg> MXLpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 M4KwZ|I{QDVyOEC3
human NSCLC cell lines NWHjN3FWSXCxcITvd4l{KEG|c3H5 MVmwMlEzPS12zszN MoTZNlRp NVP5W3VXTE2VTx?= MlLITWM2OHNicnHu[4V{KG[{b32gNE41NTMQvF2= NXm3ZY1yOjN3NkK0O|I>
human HCC cell lines NIH0SW5E\WyuII\pZYJqdGm2eTDhd5NigQ>? MX6wMlAxPS1zzszN M3u4O|Q5cA>? MYHJR|UxRTIQvF2= NH\GbG8zOzR6OUm5PS=>
Huh7 MVfLbY5ie2ViQYPzZZk> MWKx{txO MnvKOFhp NIDLfIF{cWewaf-shYNidnSueTDy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDBb5Q> NWf4WmRbOjN2OEm5PVk>
SK-HEP1 NEH3eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDT|EuOjEQvF2= M3LscFczcA>? NFjRfY9FVVOR NVvtWmhmUUN3MP-8oFHPxE1? M1TnXFI{PDd7MUO2
786-0 M2PJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j5VlEuOjEQvF2= NEXSSWI4Omh? NXLZS|hFTE2VTx?= MY\JR|Ux97zeMd88US=> M1jGVVI{PDd7MUO2
JVM2 NFrQWHJEgXSxdH;4bYNqfHliYYPzZZk> MYmwMlIuOjEQvF2= NVrhe2RJPzKq NFPobHNFVVOR M1XCdWlEPTB;MD65{txO NGDTeGEzOzJ|OE[zPS=>
EHEB Mk\wR5l1d3SxeHnjbZR6KGG|c3H5 M4fLNFAvOi1{MN88US=> MVG3Nog> M3vVSWROW09? M2m2cWlEPTB;MD63{txO M2PQ[|I{OjN6NkO5
MEC2 M1v2dWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2fOPVAvOi1{MN88US=> MYS3Nog> MYPEUXNQ M2HWeWlEPTB;MD63{txO MkHKNlMzOzh4M{m=
primary B-CLL lymphocytes M3XiZ2Fxd3C2b4Ppd{BCe3OjeR?= MYnJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m MXmyOIg> MXfEUXNQ Mn\zTWM2OO,:nEROwG0h\m:{IHHscEBx[XSrZX70dy=> MUSyN|I{QDZ|OR?=
primary B-CLL lymphocytes MknvT4lv[XOnIFHzd4F6 Mmj5TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? NFnESHEzPGh? MYjpcohq[mm2czDwO|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?= NWntbYVbOjN{M{i2N|k>
human NSCLC NYXXV5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjONE42NTMQvF2= MkXWO|Jp MX;JR|UxRTIQvF2= NIf5SmIzOjd6MUO5Ny=>
human NSCLC NYrsbFhzU2mwYYPlJGF{e2G7 M1:2NFHPxE1? NGHK[|UzPGh? NHTJXYVqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MXqyNlc5OTN7Mx?=
Y1 cell line NF7UdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiwMlHPxE1xMd88US=> M3r6TVI1cA>? MlLZSG1UVw>? NWCxT4Q2cW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= NUP6fXRlOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 M4K5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jEOWdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P NEfPTZA4Omh? NYL1eFBzT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= MWqyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 M1jtUGtqdmG|ZTDBd5NigQ>? NHPnU2JKSzVyPUGxOOKyO26P M4XHOFczcA>? MUPJR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| NEXEO2MzOjZ3M{m2Oy=>
MCF7-myr-Akt Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPyOpJQT0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= NInzPJg4Omh? NYHBSmY2T0l3ME2yPVnDuTZ6bl5vwKxNTDVy78{eNVAtODBybl2= MV6yNlY2Ozl4Nx?=
colon cancer cell lines NH72XI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\YXFAuOTEQvF2= MnTWO|Jp M1PQWGROW09? NWjn[JRQUUN3ME2x{txO M1rRS|IzPTR|OEW3
gastric cancer cell lines NYftS|hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6wMVEx|ryP NXjKcoRGPzKq MX;EUXNQ NYDCVG1LUUN3ME2yMVXPxE1? MoK5NlI2PDN6NUe=
HCT-116/HT-29/MKN-45 NGr3TJRCeG:ydH;zbZMhSXO|YYm= MVuy{txO NYHrPHl4PDiq NILGPYZ{cGmodDDpckBIOiCyaHHz[S=> MX6yNlU1Ozh3Nx?=
HT-29 and HCT-116 NHjxVnJE[XOyYYPlJIF{e2G7 MYS1{txO MYKyOIg> NILKVJpqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= MVmyNlU1Ozh3Nx?=
MM cell lines MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnSRlAyOM7:TR?= MUmyOIg> Ml25SG1UVw>? M3XZWmlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>? NF\NPHUzOjJyN{S4OS=>
ARP-1 MUTBdI9xfG:|aYOgRZN{[Xl? NGK5W3AyOM7:TR?= M2e0bFI1cA>? Mnn5SG1UVw>? M3jxTYlv\HWlZYOgUW0h[2WubDDhdI9xfG:|aYOgeIhzd3WpaDDjZZNx[XOnIHHjeIl3[XSrb36= Ml;1NlIzODd2OEW=
SNU-601 M4T0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7rZ45WPzKq M{PHXWROW09? M2DXS2lEPTB;MD64NVbDuTBwME[z{txO MWeyNlE2QThzNB?=
SNU-1 NX75bWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVO3Nog> MXTEUXNQ M{T2XWlEPTB;MT6wPFLDuTBwMEK4{txO MVKyNlE2QThzNB?=
SNU-668 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XKNFczcA>? MXnEUXNQ MYrJR|UxRTFwNUe5xtExNjB5NN88US=> NGHwcHEzOjF3OUixOC=>
AGS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3Nog> MVjEUXNQ MVfJR|UxRTFwN{G0xtExNjFzN988US=> NUTn[5ZiOjJzNUm4NVQ>
SNU-216 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvBSGI4Omh? MVvEUXNQ M{DkV2lEPTB;Mj62PVLDuTBwMEiy{txO MWCyNlE2QThzNB?=
SNU-5 NGjUToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX6UFRjPzKq NV;uRow5TE2VTx?= NGrYcplKSzVyPUGuN|UyyrFyLkC5Ne69VQ>? M3roblIzOTV7OEG0
SNU-638 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu0TlE4Omh? NVXMdnAzTE2VTx?= NFvj[VdKSzVyPUKuNlgzyrFyLkC1N:69VQ>? MUmyNlE2QThzNB?=
SNU-16 M3fZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HPWw4Omh? NILmcHlFVVOR M1XGbmlEPTB;MT61O|PDuTBwMECx{txO M2LEdFIzOTV7OEG0
SNU-484 M2nXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwUmo4Omh? MVPEUXNQ M1Xa[mlEPTB;MT63NljDuTBwMES1{txO MkWwNlIyPTl6MUS=
SNU-620 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK3Nog> MYPEUXNQ NVnVVYN5UUN3ME2yMlk{QcLzMD6wNFHPxE1? NVTsNGVWOjJzNUm4NVQ>
SNU-719 M17rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG3Nog> MYXEUXNQ MYTJR|UxRTNwMEO3xtExNjB|Mt88US=> MXiyNlE2QThzNB?=
glioma cell lines NUPsOIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS5O|Jp MYPJR|UxRTFvMt88US=> NWPWbXRMOjJyNkWwPFA>
U87 MmWxRZBweHSxc3nzJGF{e2G7 MkXWNu69VQ>? NY\KVYd3PzKq MnjlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO= NVfyS21XOjJyNkWwPFA>

... Click to View More Cell Line Experimental Data
体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+ddH2O 		15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2
CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870726 Terminated c-MET Inhibitor; PI3K Inhibitor PTEN Mutations Homozygous Del. of PTEN or PTEN Neg. by IHC c-Met Ampli. by FISH INC280 BKM120 Buparlisib; Recurrent GBM Novartis Pharmaceuticals|Novartis January 9 2014 Phase 1|Phase 2
NCT01820325 Terminated Non-Small Cell Lunch Cancer Novartis Pharmaceuticals|Novartis September 9 2013 Phase 1
NCT01512251 Completed BRAF Mutant Metastatic Melanoma University of California San Francisco|Novartis June 9 2012 Phase 1|Phase 2
NCT01610284 Active not recruiting Breast Cancer Novartis Pharmaceuticals|Novartis August 7 2012 Phase 3
NCT02058381 Completed Pre-menopausal Breast Cancer|PI3K Pathway Inhibition Novartis Pharmaceuticals|Novartis May 6 2014 Phase 1
NCT02340780 Active not recruiting Chronic Lymphocytic Leukemia Canadian Cancer Trials Group|Novartis January 30 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项
Selleck产品目录册

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032)是一种有效，下一代的β亚型PI3K抑制剂，作用于PI3Kα/δ/γ， IC50分别为0.29 nM/0.12 nM/0.97nM，比作用于PI3Kβ选择性高10倍以上。

  • Pilaralisib (XL147) New

    Pilaralisib (XL147)是一种选择性的可逆I型PI3K抑制剂，作用于PI3Kα/δ/γ，在无细胞试验中IC50为 39 nM/36 nM/23 nM，对PI3Kβ作用较低。Phase 1/2。

  • GNE-317 New

    GNE-317 是一种有效的，大脑渗透性 PI3K 抑制剂。

  • LY294002

    LY294002 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。

    Features:Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

  • Wortmannin

    Wortmannin是一种首次命名的PI3K抑制剂，在无细胞试验中IC50为3 nM，对 PI3K 家族的选择性较低。也会抑制自噬体的形成，并有效抑制DNA-PK/ATM，在无细胞试验中IC50为16 nM和150 nM。

  • Dactolisib (BEZ235, NVP-BEZ235)

    Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。 在 3T3TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Phase 2。

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Phase 2。

  • Alpelisib (BYL719)

    Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID